A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants
← catalyst calendarNCT07433179 · readout ≤ 193 d
Sponsored by Septerna, Inc. (industry) · SEPN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-04 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: SEP-479
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFFrequency of treatment emergent adverse events
measured From enrollment to end of follow up visit, up to approximately 2 months
Permalink · SEPN's whole pipeline · Catalyst calendar · Every registered study · What changed